Plain-English translation of NCT04946370 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Prostate Cancer research guide →Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing — a medication that helps your immune system fight cancer cells — combined with standard prostate cancer hormonal therapy. Half the participants will also receive a single dose of a radiation-based therapy called , which is designed to deliver powerful radiation directly to prostate cancer cells. The study will compare whether adding this radiation therapy improves outcomes compared to the immune-boosting medication and hormonal therapy alone.
Advanced prostate cancer that no longer responds to hormone treatment is hard to treat and often continues to grow. This trial is exploring whether combining immune-boosting therapy with a targeted radiation approach can offer better control of the disease than current standard treatments.
You likely qualify if…
You likely don't qualify if…
The study has two phases. In Phase I, doctors will first figure out the safest and most effective dose of the radiation therapy to use. In Phase II, you will be randomly assigned to receive either the immune-boosting medication with hormonal therapy alone, or the same combination plus the radiation therapy. You will receive the immune-boosting medication as an infusion every 6 weeks for up to 2 years, and you may receive the radiation therapy as a single dose early in treatment. You will have CT scans, bone scans, and specialized imaging tests every 12 weeks, along with regular blood tests to monitor your response and safety.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
United States